Lee Patricia K, Kieffer Tara L, Siliciano Robert F, Nettles Richard E
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Antimicrob Chemother. 2006 May;57(5):803-5. doi: 10.1093/jac/dkl092. Epub 2006 Mar 13.
Many patients on highly active antiretroviral therapy (HAART) who achieve undetectable HIV-1 RNA levels experience transient episodes of detectable viraemia or blips, suggesting there is incomplete suppression of viral replication. This raises concern that drug resistance mutations could develop and cause eventual treatment failure. However, data from recent studies indicate that most blips are actually random biological and statistical variations around a mean viral load below detectable levels (<50 copies/mL) or due to false elevations of viral load from laboratory processing artefacts. Blips are not typically associated with the development of resistance mutations and most importantly are not associated with virological or clinical failure of previously adequate HAART.
许多接受高效抗逆转录病毒疗法(HAART)且HIV-1 RNA水平检测不到的患者会经历可检测到病毒血症或病毒载量波动的短暂发作,这表明病毒复制未得到完全抑制。这引发了人们对耐药性突变可能产生并最终导致治疗失败的担忧。然而,近期研究数据表明,大多数病毒载量波动实际上是围绕低于可检测水平(<50拷贝/毫升)的平均病毒载量的随机生物学和统计学变异,或者是由于实验室处理假象导致病毒载量的假性升高。病毒载量波动通常与耐药性突变的发生无关,最重要的是,与先前充分的HAART的病毒学或临床失败无关。